Matthew Biegler analyst OPPENHEIMER

Currently out of the existing stock ratings of Matthew Biegler, 110 are a BUY (92.44%), 9 are a HOLD (7.56%).

Matthew Biegler

Work Performance Price Targets & Ratings Chart

Analyst Matthew Biegler, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 29.7% that have a potential upside of 37.7% achieved within 102 days.

Matthew Biegler’s has documented 217 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NRIX, Nurix Therapeutics  at 09-Oct-2025.

Wall Street Analyst Matthew Biegler

Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for VOR (VOR BIOPHARMA) at 3/21/2025. The price target of $8 was fulfilled within 182 days with a profit of $7.13 (819.54%) receiving and performance score of 45.03.

Average potential price target upside

FATE Fate Therapeutics MRKR Marker Therapeutics TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals Llc BPMC Blueprint Medicines Corp FIXX Homology Medicines FULC Fulcrum Therapeutics NKTX Nkarta  VOR Vor Biopharma CELU Celularity MDNA Medicenna Therapeutics Corp TYRA Tyra Biosciences IDYA Ideaya Biosciences RLAY Relay Therapeutics  PRTG Portage Biotech APTO Aptose Biosciences OLMA Olema Pharmaceuticals DAWN Day One Biopharmaceuticals ALLO Allogene Therapeutics ARVN Arvinas ORIC Oric Pharmaceuticals  RNAC Cartesian Therapeutics NRIX Nurix Therapeutics 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$2.5

$0.86 (52.44%)

$4

2 months 3 days ago
(12-Aug-2025)

2/4 (50%)

$1.37 (121.24%)

49

Buy

$2

$0.36 (21.95%)

$6

5 months 2 days ago
(13-May-2025)

6/8 (75%)

$1.04 (108.33%)

91

Hold

$4

$2.36 (143.90%)

$28

5 months 2 days ago
(13-May-2025)

1/2 (50%)

$3.04 (316.67%)

33

Hold

$3

$1.36 (82.93%)

7 months 6 days ago
(09-Mar-2025)

2/4 (50%)

$2.07 (222.58%)

111

Buy

$145

7 months 10 days ago
(05-Mar-2025)

0/1 (0%)

$52.99 (57.59%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Biegler is most bullish on?

Potential upside of $18.24 has been obtained for NRIX (NURIX THERAPEUTICS )

Which stock is Matthew Biegler is most reserved on?

Potential downside of -$1.68 has been obtained for ORIC (ORIC PHARMACEUTICALS )

What Year was the first public recommendation made by Matthew Biegler?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?